EP1379132A4 - Sezernierte humanproteine - Google Patents

Sezernierte humanproteine

Info

Publication number
EP1379132A4
EP1379132A4 EP02760994A EP02760994A EP1379132A4 EP 1379132 A4 EP1379132 A4 EP 1379132A4 EP 02760994 A EP02760994 A EP 02760994A EP 02760994 A EP02760994 A EP 02760994A EP 1379132 A4 EP1379132 A4 EP 1379132A4
Authority
EP
European Patent Office
Prior art keywords
secreted proteins
human secreted
human
proteins
secreted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02760994A
Other languages
English (en)
French (fr)
Other versions
EP1379132A2 (de
Inventor
Craig A Rosen
Steven M Ruben
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of EP1379132A2 publication Critical patent/EP1379132A2/de
Publication of EP1379132A4 publication Critical patent/EP1379132A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP02760994A 2001-03-21 2002-03-19 Sezernierte humanproteine Withdrawn EP1379132A4 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US27734001P 2001-03-21 2001-03-21
US277340P 2001-03-21
US30617101P 2001-07-19 2001-07-19
US306171P 2001-07-19
US33128701P 2001-11-13 2001-11-13
US331287P 2001-11-13
PCT/US2002/008278 WO2002102994A2 (en) 2001-03-21 2002-03-19 Human secreted proteins

Publications (2)

Publication Number Publication Date
EP1379132A2 EP1379132A2 (de) 2004-01-14
EP1379132A4 true EP1379132A4 (de) 2009-07-01

Family

ID=27402891

Family Applications (7)

Application Number Title Priority Date Filing Date
EP02799146A Withdrawn EP1390390A4 (de) 2001-03-21 2002-03-19 Sezernierte humanproteine
EP02782476A Withdrawn EP1414845A4 (de) 2001-03-21 2002-03-19 Sezernierte humanproteine
EP02759068A Withdrawn EP1404702A4 (de) 2001-03-21 2002-03-19 Sezernierte humanproteine
EP02780789A Withdrawn EP1423134A2 (de) 2001-03-21 2002-03-19 Sezernierte humanproteine
EP02723499A Withdrawn EP1379264A4 (de) 2001-03-21 2002-03-19 Sezernierte humanproteine
EP02749512A Withdrawn EP1381622A2 (de) 2001-03-21 2002-03-19 Sezernierte humanproteine
EP02760994A Withdrawn EP1379132A4 (de) 2001-03-21 2002-03-19 Sezernierte humanproteine

Family Applications Before (6)

Application Number Title Priority Date Filing Date
EP02799146A Withdrawn EP1390390A4 (de) 2001-03-21 2002-03-19 Sezernierte humanproteine
EP02782476A Withdrawn EP1414845A4 (de) 2001-03-21 2002-03-19 Sezernierte humanproteine
EP02759068A Withdrawn EP1404702A4 (de) 2001-03-21 2002-03-19 Sezernierte humanproteine
EP02780789A Withdrawn EP1423134A2 (de) 2001-03-21 2002-03-19 Sezernierte humanproteine
EP02723499A Withdrawn EP1379264A4 (de) 2001-03-21 2002-03-19 Sezernierte humanproteine
EP02749512A Withdrawn EP1381622A2 (de) 2001-03-21 2002-03-19 Sezernierte humanproteine

Country Status (4)

Country Link
EP (7) EP1390390A4 (de)
AU (6) AU2002324424A1 (de)
CA (7) CA2441417A1 (de)
WO (7) WO2003004622A2 (de)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999002546A1 (en) 1997-07-08 1999-01-21 Human Genome Sciences, Inc. 123 human secreted proteins
US7196164B2 (en) 1997-07-08 2007-03-27 Human Genome Sciences, Inc. Secreted protein HHTLF25
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US20030149531A1 (en) 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US20060052321A1 (en) 2002-04-05 2006-03-09 Raitano Arthur B Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
AU757698C (en) 1998-06-01 2004-04-08 Agensys, Inc. Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
US20040141975A1 (en) 1998-06-01 2004-07-22 Raitano Arthur B. Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
JP5550799B2 (ja) 1999-01-15 2014-07-16 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｔｗｅａｋのアンタゴニストおよびｔｗｅａｋレセプターのアンタゴニスト、ならびに免疫学的障害を処置するためのこれらの使用
EP1666490A3 (de) * 2000-07-25 2006-11-02 Genentech, Inc. Sekretierte und transmembrane Polypeptide und dafür kodierende Nukleinsäuren
US7291719B2 (en) 2000-07-25 2007-11-06 Genentech, Inc. PRO4332 antibodies
WO2002048370A2 (en) 2000-10-31 2002-06-20 Diadexus, Inc. Compositions and methods relating to colon specific genes and proteins
US20020111302A1 (en) * 2000-11-30 2002-08-15 Y. Tom Tang Novel nucleic acids and polypeptides
US7736654B2 (en) 2001-04-10 2010-06-15 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
US7164007B2 (en) 2001-06-20 2007-01-16 Genentech, Inc. Anti-PR020044 antibodies
ES2537074T3 (es) 2001-09-06 2015-06-02 Agensys, Inc. Ácido nucleico y proteína correspondiente denominados STEAP-1 útiles en el tratamiento y la detección de cáncer
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
CA2463596A1 (en) 2001-10-12 2003-04-24 Yamanouchi Pharmaceutical Co., Ltd. Method of screening cell death inhibitor
EA011607B1 (ru) 2002-04-09 2009-04-28 Байоджен Айдек Ма Инк. Способ лечения заболеваний, связанных с tweak
AU2003900747A0 (en) * 2003-02-18 2003-03-06 Garvan Institute Of Medical Research Diagnosis and treatment of pancreatic cancer
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
WO2005019258A2 (en) * 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP2380985B1 (de) * 2003-09-23 2014-01-01 University of North Carolina at Chapel Hill Vitamin-K-Epoxid-Reduktase exprimierende Zellen und deren Verwendung
ATE466074T1 (de) * 2003-10-14 2010-05-15 Baxter Int Vkorc1 (vitamin k epoxide recycling polypeptide), ein therapeutisches ziel für coumarin und deren derivate
EP1714154A2 (de) * 2004-02-03 2006-10-25 Bayer HealthCare AG Diagnostika und therapeutika für mit plasma-glutamat-carboxypeptidase (pgcp) assoziierten krankheiten
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
ES2443996T3 (es) 2004-04-22 2014-02-21 Agensys, Inc. Anticuerpos y moléculas derivadas de los mismos que se unen a proteínas STEAP-1
JP2008514187A (ja) * 2004-09-01 2008-05-08 ダイナバックス テクノロジーズ コーポレイション 先天性免疫応答及び自己免疫疾患の阻害法及び阻害用組成物
EP1799849A4 (de) * 2004-09-07 2008-07-09 Telethon Inst For Child Health Mittel zur behandlung oder vorbeugung einer allergischen erkrankung
WO2006026808A1 (en) * 2004-09-07 2006-03-16 Telethon Institute For Child Health Research Method of diagnosing and/or predicting the development of an allergic disorder
EP2529619B1 (de) 2005-02-17 2015-09-23 Biogen MA Inc. Behandlung neurologischer Störungen
ES2397530T3 (es) 2005-02-28 2013-03-07 Baxter International Inc. Coexpresión recombinante de la subunidad 1 de la epóxido reductasa de la vitamina K para mejorar la expresión de proteína dependiente de la vitamina K
AU2005329450A1 (en) 2005-03-15 2006-09-28 University Of North Carolina At Chapel Hill Methods and compositions for producing active Vitamin K-dependent proteins
JP5339901B2 (ja) 2005-05-10 2013-11-13 バイオジェン・アイデック・エムエイ・インコーポレイテッド 炎症傷害の処置および評価
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
WO2007025347A1 (en) * 2005-09-01 2007-03-08 Howard Florey Institute Of Experimental Physiology And Medicine Prophylactic and therapeutic agents and uses therefor
GB0521488D0 (en) * 2005-10-21 2005-11-30 Ares Trading Sa Integral membrane protein
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
KR20140116546A (ko) 2006-10-27 2014-10-02 제넨테크, 인크. 항체 및 면역접합체 및 이들의 용도
CA2667894A1 (en) 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonists of pcsk9
US8093222B2 (en) 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
EP2142217B1 (de) * 2007-03-27 2014-11-05 Merck Sharp & Dohme Corp. Verfahren zum nachweis von automatisch aufbereitetem sezerniertem pcsk9
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
CA2703931C (en) 2007-10-26 2016-08-16 Dynavax Technologies Corporation Methods and compositions for inhibition of immune responses and autoimmunity
CA2707182C (en) * 2007-11-30 2017-12-12 Siemens Healthcare Diagnostics Inc. Adiponectin receptor fragments and methods of use
AR070315A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
AR070316A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
WO2010068526A1 (en) 2008-12-12 2010-06-17 Merck Sharp & Dohme Corp. Pcsk9 immunoassay
CN102596249A (zh) 2009-10-30 2012-07-18 默沙东公司 Ax1和ax189 pcsk9拮抗剂和变体
WO2011053783A2 (en) 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Ax213 and ax132 pcsk9 antagonists and variants
CN103153346A (zh) 2010-06-16 2013-06-12 戴纳瓦克斯技术公司 使用tlr7和/或tlr9抑制剂的治疗方法
BR112013005872A2 (pt) 2010-09-22 2019-09-24 Alios Biopharma Inc compostos, composição farmacêutica e respectivos usos
EP2655607A4 (de) 2010-12-21 2014-05-14 Univ North Carolina Verfahren und zusammensetzungen zur herstellung aktiver vitamin-k-abhängiger proteine
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
EP2794630A4 (de) 2011-12-22 2015-04-01 Alios Biopharma Inc Substituierte phosphorthioat-nukleotidanaloga
WO2013142124A1 (en) 2012-03-21 2013-09-26 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
US9012427B2 (en) 2012-03-22 2015-04-21 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US9051378B1 (en) 2014-07-15 2015-06-09 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US9682218B2 (en) 2013-12-23 2017-06-20 Carefusion 2200, Inc. Pleurodesis device and method
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
EP3534947A1 (de) 2016-11-03 2019-09-11 Kymab Limited Antikörper, kombinationen mit antikörpern, biomarker, verwendungen und verfahren
EP3559223A1 (de) 2016-12-23 2019-10-30 President and Fellows of Harvard College Gen-editing von pcsk9
SG11201909218RA (en) 2017-04-03 2019-11-28 Hoffmann La Roche Antibodies binding to steap-1
US10450119B2 (en) * 2017-06-22 2019-10-22 The Procter & Gamble Company Films including a water-soluble layer and a vapor-deposited inorganic coating
EP3641951B1 (de) 2017-06-22 2023-09-20 The Procter & Gamble Company Filme mit einer wasserlöslichen schicht und einer aufgedämpften organischen beschichtung
GB2632565B (en) 2020-04-09 2025-06-04 Verve Therapeutics Inc Base editing of PCSK9 and methods of using same for treatment of disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000004140A1 (en) * 1998-07-15 2000-01-27 Human Genome Sciences, Inc. 71 human secreted proteins
WO2002026931A2 (en) * 2000-09-25 2002-04-04 Human Genome Sciences, Inc. 71 human secreted proteins

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100236393B1 (ko) * 1996-02-02 1999-12-15 나까니시 히로유끼 사람성장호르몬을 함유하는 의약제제
US5858716A (en) * 1997-05-30 1999-01-12 Smithkline Beecham Corporation H2CAA71 polynucleotides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000004140A1 (en) * 1998-07-15 2000-01-27 Human Genome Sciences, Inc. 71 human secreted proteins
WO2002026931A2 (en) * 2000-09-25 2002-04-04 Human Genome Sciences, Inc. 71 human secreted proteins

Also Published As

Publication number Publication date
WO2002102993A2 (en) 2002-12-27
CA2441416A1 (en) 2003-01-16
AU2002332391A1 (en) 2003-01-02
WO2002102994A2 (en) 2002-12-27
CA2441832A1 (en) 2002-12-27
AU2002363296A1 (en) 2003-05-12
AU2002320013A1 (en) 2002-11-18
AU2002326293A1 (en) 2003-01-02
WO2002102994A3 (en) 2003-07-24
WO2002090526A3 (en) 2003-10-30
CA2441840A1 (en) 2002-11-28
CA2441702A1 (en) 2002-12-27
EP1414845A4 (de) 2009-07-08
WO2002095010A2 (en) 2002-11-28
WO2002095010A3 (en) 2004-02-12
EP1379264A1 (de) 2004-01-14
WO2002076488A1 (en) 2002-10-03
WO2003004622A3 (en) 2004-02-19
WO2002102993A3 (en) 2004-03-25
WO2003004622A2 (en) 2003-01-16
WO2003038063A2 (en) 2003-05-08
CA2441417A1 (en) 2002-11-14
EP1379264A4 (de) 2009-07-08
CA2441397A1 (en) 2002-10-03
EP1414845A2 (de) 2004-05-06
EP1379132A2 (de) 2004-01-14
WO2003038063A3 (en) 2003-12-11
EP1404702A2 (de) 2004-04-07
EP1423134A2 (de) 2004-06-02
EP1390390A2 (de) 2004-02-25
AU2002324424A1 (en) 2002-12-03
CA2441755A1 (en) 2003-05-08
EP1390390A4 (de) 2009-07-08
EP1404702A4 (de) 2009-07-08
AU2002354719A1 (en) 2003-01-21
EP1381622A2 (de) 2004-01-21
WO2002090526A2 (en) 2002-11-14

Similar Documents

Publication Publication Date Title
EP1414845A4 (de) Sezernierte humanproteine
EP1385381A4 (de) Sezernierte humanproteine
EP1181390A4 (de) 27 menschliche, sekretierte proteine
EP1391209A4 (de) Proteinzubereitung
EP1165827A4 (de) 45 humane sekretierte proteine
EP1175439A4 (de) 49 humane sekretierte proteine
EP1159284A4 (de) 33 human sekrteierte proteine
EP1189917A4 (de) 48 menschliche sekretierte proteine
EP1368468A4 (de) Menschliche sezernierte proteine
EP1185543A4 (de) 50 human-sekretierte proteine
EP1173477A4 (de) 49 humane sekretierte Proteine
EP1171460A4 (de) 48 menschliche sekretierte proteine
EP1165828A4 (de) 50 menschliche sekretierte proteine
EP1317471A4 (de) 21 menschliche sekretierte proteine
EP1404807A4 (de) 20 sezernierte humanproteine
EP1185285A4 (de) 49 humane sekretierte proteine
EP1322657A4 (de) 22 humane sezernierte proteine
EP1171626A4 (de) 50 humane sekretierte proteine
EP1322659A4 (de) 21 humane sezernierte proteine
EP1165123A4 (de) 48 menschliche sekretierte proteine
EP1165591A4 (de) 47 menschliche sekretierte proteine
EP1181303A4 (de) 50 human-ausgeschiedene proteine
EP1317467A4 (de) 7 menschliche sekretierte proteine
EP1192171A4 (de) 48 menschliche sekretierte proteine
EP1165590A4 (de) 49 menschliche sekretierte proteine

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20031021

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20090603

RIC1 Information provided on ipc code assigned before grant

Ipc: C07H 21/02 20060101ALI20090527BHEP

Ipc: C07K 1/00 20060101AFI20090527BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090903